The dark skin pigment melanin protects us from the sun’s damaging rays by absorbing light energy and converting it to heat. This could make it a very effective tool in tumor diagnosis and treatment, as demonstrated by a team from the Technical University of Munich (TUM) and Helmholtz Zentrum München. The scientists managed to create melanin-loaded cell membrane derived nanoparticles, which improved tumor imaging in an animal model while also slowing the growth of the tumor.
Nanoparticles are considered a promising weapon in the fight against tumors due to the fact that tumor tissue absorbs them more readily than healthy cells because their vascular system is more permeable. A good example is provided by outer membrane vesicles (OMVs), which are basically small bubbles surrounded by bacterial membrane. These 20- to 200-nanometer particles are of interest because they are biocompatible, biodegradable and can be easily and inexpensively produced in bacteria, even in large volumes. Once loaded with medicinal active agents, they are easy to administer.
NANOPARTICLES CARRYING A BLACK CARGO
The huge potential of OMVs in tumor diagnosis and treatment has been demonstrated by Prof. Vasilis Ntziachristos, Professor of Biological Imaging at TUM, and his team. Their work builds on the characteristic properties of OMVs and melanin.’
Dr. Vipul Gujrati, first author of the study, explains the principle: “Melanin absorbs light very readily – even in the infrared spectrum. We use precisely this light in our optoacoustic imaging technique for tumor diagnosis. It simultaneously converts this absorbed energy into heat, which is then emitted. Heat is also a way to combat tumors – other researchers are currently exploring this method in clinical trials.”
Optoacoustics, a method which has been significantly advanced by Ntziachristos, combines the benefits of optical imaging and ultrasound technology. Weak laser pulses gently heat the tissue, causing it to briefly expand very slightly. Ultrasound signals are produced when the tissue contracts again as it cools down. The measured signals vary depending on the tissue type. The scientists record them with special detectors and “translate” them into three-dimensional images. Sensor molecules or probes (such as OMVs) can improve the specificity and accuracy of the technique even further.
HEAT BUILD-UP REDUCES TUMOR GROWTH
The scientists initially had to overcome a problem specific to melanin: It is not very water-soluble and therefore difficult to administer. This is where the OMVs came into play. The researchers engineered bacteria in such a way that they produce melanin and store it in their membrane derived nanoparticles. They then tested the black nanoparticles in mice which had tumors in their lower back region. The particles were injected directly into the tumor, which was excited with infrared laser pulses as part of the optoacoustic procedure.
OMVs proved to be suitable sensor probes for this diagnosis technique because they delivered sharp, high-contrast images of the tumor. They are also well-suited to photothermal therapy approaches, where the tumor tissue is heated with stronger laser pulses in order to kill the cancer cells. The melanin in the nanoparticles caused the temperature of the tumor tissue to rise from 37 °C to up to 56 °C. Control tumors with no melanin only reached a maximum temperature of 39 °C. In the ten days following the treatment, the tumors grew at a significantly slower rate than those in the control group that had not received melanin OMVs. This heat effect was amplified by another positive effect of the particles: By causing a slight non-specific inflammation in the tumor tissue, the immune system was triggered to attack the tumor.
“Our melanin nanoparticles fit into the new medical field of theranostics – where therapy and diagnostics are combined. This makes them a highly interesting option for use in clinical practice,” says Ntziachristos. The scientists will now develop their OMVs further to bring them into clinical use in the future.
Learn more: Black nanoparticles slow the growth of tumors
The Latest on: Theranostics
[google_news title=”” keyword=”theranostics” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Theranostics
- Healthcare trends and transformation in the year aheadon April 28, 2024 at 5:06 am
In just a couple of weeks it will have been one year since the lifting of the COVID-19 public health emergency. While our community has in many ways seen a ...
- APCCC 2024: PSMA Radioligand Therapy – State of the Arton April 27, 2024 at 6:35 am
(UroToday.com) The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) held in Lugano, Switzerland between April 25 th and 27 th was host to PSMA for Diagnostic and Treatment session. Dr. Ken ...
- AUA 2024: Awaiting New Data in the Treatment of Metastatic Prostate Canceron April 26, 2024 at 1:59 pm
Cite this: AUA 2024: Awaiting New Data in the Treatment of Metastatic Prostate Cancer - Medscape - Apr 26, 2024.
- Monument Health invests in future of nuclear pharmacy in Rapid Cityon April 24, 2024 at 10:51 pm
RAPID CITY, S.D. (KOTA) - Last month Monument Health opened its nuclear pharmacy facility. The building joins a facility in Sioux Falls as the only two of their kind in South Dakota. But what does ...
- Cancer Theranostics With Gold Nanoshellson April 19, 2024 at 4:59 pm
AuNSs generate heat as a result of irradiation by a continuous laser. The temperature increase (ΔT) depends on the laser power and AuNS concentration. Both high-temperature thermal ablation and ...
- GE HealthCare (GEHC), RSNA Unite to Aid Breast Cancer Imagingon April 17, 2024 at 7:48 am
GE HealthCare Technologies Inc. GEHC and the Radiological Society of North America (RSNA) recently announced their partnership to offer mammography equipment, training, and educational materials to ...
- Aptamer-based theranostics in oncologyon April 14, 2024 at 5:00 pm
Aptamer-based theranostics have gained attention in the field of cancer research and treatment. Aptamers can be used as targeting ligands for the delivery of therapeutic agents to cancer cells ...
- Global Theranostics Market Size To Worth USD 3.3 Billion By 2033 | CAGR of 5.68%on April 12, 2024 at 5:00 am
New York, United States , April 12, 2024 (GLOBE NEWSWIRE) -- The Global Theranostics Market Size is to Grow from USD 1.9 Billion in 2023 to USD 3.3 Billion by 2033, at a Compound Annual Growth ...
- Outlining the future of theranostics in neurooncologyon February 15, 2024 at 12:17 pm
More information: Nelleke Tolboom et al, Theranostics in Neurooncology: Heading Toward New Horizons, Journal of Nuclear Medicine (2023). DOI: 10.2967/jnumed.123.266205 Provided by Society of ...
- Radiopharm Theranostics Ltd.on April 2, 2022 at 3:18 pm
No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...
via Bing News